- Home
- Publications
- Publication Search
- Publication Details
Title
The application of BH3 mimetics in myeloid leukemias
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 12, Issue 2, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-26
DOI
10.1038/s41419-021-03500-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia
- (2020) Xue Yi et al. CLINICAL CANCER RESEARCH
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML
- (2020) Myriam Hormi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
- (2019) Claudia Iavarone et al. MOLECULAR CANCER THERAPEUTICS
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia
- (2019) Jing-dong Zhou et al. Diagnostic Pathology
- Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity
- (2019) Zoltan Szlávik et al. JOURNAL OF MEDICINAL CHEMISTRY
- TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1
- (2019) Bing Z Carter et al. BLOOD
- Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)
- (2019) Wittawat Chantkran et al. BLOOD
- AZD4573 is a highly selective CDK9 inhibitor that suppresses Mcl-1 and induces apoptosis in hematological cancer cells.
- (2019) Justin Cidado et al. CLINICAL CANCER RESEARCH
- Mitochondria as multifaceted regulators of cell death
- (2019) Florian J. Bock et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
- (2018) Yichao Wan et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin
- (2018) Katja Seipel et al. HAEMATOLOGICA
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
- (2018) Ryan S. Soderquist et al. Nature Communications
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
- (2017) Joel D. Leverson et al. Cancer Discovery
- iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry
- (2016) Jeremy Ryan et al. BIOLOGICAL CHEMISTRY
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
- (2016) Bing Z. Carter et al. Science Translational Medicine
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Mutations in AML: prognostic and therapeutic implications
- (2016) C. D. DiNardo et al. Hematology-American Society of Hematology Education Program
- Acute Myeloid Leukemia: A Concise Review
- (2016) Jennifer Saultz et al. Journal of Clinical Medicine
- Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
- (2016) Valentina Cappello et al. Scientific Reports
- The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
- (2015) A. Baker et al. CANCER RESEARCH
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
- (2015) Avi Ashkenazi JOURNAL OF CLINICAL INVESTIGATION
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
- (2015) Jo Ishizawa et al. PLoS One
- The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
- (2015) Tun Kiat Ko et al. Oncotarget
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells
- (2014) Mariarita Perri et al. EXPERIMENTAL CELL RESEARCH
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
- (2014) J M Bogenberger et al. LEUKEMIA
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
- (2014) James M. Bogenberger et al. LEUKEMIA & LYMPHOMA
- Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage
- (2014) Chengzhi Xie et al. Molecular Oncology
- Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells
- (2013) Jing Yang et al. APOPTOSIS
- miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein
- (2013) Yajuan Li et al. EXPERIMENTAL CELL RESEARCH
- Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure
- (2013) R. L. Thomas et al. GENES & DEVELOPMENT
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
- (2012) Twee Tsao et al. ANNALS OF HEMATOLOGY
- How I treat CML blast crisis
- (2012) R. Hehlmann BLOOD
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
- (2012) M. Rahmani et al. BLOOD
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- ABT-737 increases tyrosine kinase inhibitor–induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38− population to imatinib
- (2012) Kelly Airiau et al. EXPERIMENTAL HEMATOLOGY
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors
- (2011) D H Mak et al. LEUKEMIA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Molecular biology of Bax and Bak activation and action
- (2010) Dana Westphal et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
- (2010) Zhifu Xiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Resistance to Imatinib: Mutations and Beyond
- (2010) Paul La Rosée et al. SEMINARS IN HEMATOLOGY
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation
- (2009) G. Yoshimoto et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
- (2008) G Kroemer et al. CELL DEATH AND DIFFERENTIATION
- Living with death: the evolution of the mitochondrial pathway of apoptosis in animals
- (2008) A Oberst et al. CELL DEATH AND DIFFERENTIATION
- Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
- (2008) W Zhang et al. LEUKEMIA
- BCL-2 family antagonists for cancer therapy
- (2008) Guillaume Lessene et al. NATURE REVIEWS DRUG DISCOVERY
- The BCL-2 protein family: opposing activities that mediate cell death
- (2007) Richard J. Youle et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now